Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Operating Expenses (2016 - 2025)

China Pharma Holdings' Operating Expenses history spans 16 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 30.47% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $3.1 million, up 19.36%, while the annual FY2025 figure was $3.1 million, 19.36% up from the prior year.
  • Operating Expenses reached $1.4 million in Q4 2025 per CPHI's latest filing, up from $568491.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $1.4 million in Q4 2025 to a low of $309647.0 in Q2 2023.
  • Average Operating Expenses over 5 years is $722296.1, with a median of $598980.0 recorded in 2023.
  • Peak YoY movement for Operating Expenses: plummeted 53.38% in 2021, then soared 50.24% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $950626.0 in 2021, then increased by 27.46% to $1.2 million in 2022, then decreased by 8.78% to $1.1 million in 2023, then decreased by 6.32% to $1.0 million in 2024, then skyrocketed by 30.47% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Operating Expenses are $1.4 million (Q4 2025), $568491.0 (Q3 2025), and $565110.0 (Q2 2025).